Home › Opioid Overdose › NCT06051890

Assessing Optimal XRB Initiation Points in Jail

Assessing Optimal Extended-Release Buprenorphine (XRB) Initiation Points in Jail

Who can join

All ages · Men

Inclusion Criteria:

* Incarcerated men able to provide written informed consent in English.\*
* Unsentenced.
* Entering the facility with a prescription for SLB and receiving SLB for at least the previous 3 days.
* Minimum anticipated jail stay is 4 days.
* Willing to accept being randomized to the experimental condition (i.e., transitioning to XRB while incarcerated).

Exclusion Criteria:

* Sentenced.
* Allergy, hypersensitivity or medical contraindication to either medication.
* Chronic pain requiring opioid pain management or other contraindicated medications.

About the study

This application describes a 3-year, randomized controlled trial. Eligible, consenting adults (N=200) with existing sublingual buprenorphine (SLB) prescriptions who enter Middlesex County House of Corrections (MCHOC) as pre-trial detainees will be randomized at admission on a 1:1 basis to be inducted onto extended-release buprenorphine (XRB) at the time of admission (experimental condition) or remain in SLB (E-TAU; all participants will also receive naloxone). The two approaches will be compared with regard to (1) the percentage of participants released from jail with at least 7 days of buprenorphine in their system, (2) percentage of participants continuing MOUD treatment in the community, and (3) infractions related to buprenorphine diversion.

What is being tested

• Extended-Release Buprenorphine (XRB) (drug)
• Sublingual Buprenorphine (SLB) (drug)

Sponsor: NYU Langone Health · Participants: 50 · Started: Jun 2, 2025

Contact the study team

• David Farabee · Phone: 310-963-0009

Official record on ClinicalTrials.gov — NCT06051890

Locations in the U.S.

Conditions

• Opioid Overdose

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.